Restless Legs Syndrome (RLS) Therapeutics – Competitive Landscape, Epidemiology Forecast, and Pipeline Analysis, 2018

Chapter 1. Research Background

1.1 Research Objectives

1.2 Definition

1.3 Research Scope

1.3.1 Pipeline Analysis by Phase

1.3.2 Pipeline Analysis by Molecule Type

1.3.3 Pipeline Analysis by Route of Administration

1.4 Key Stakeholders

Chapter 2. Research Methodology

2.1 Secondary Research

2.2 Primary Research

2.2.1 Breakdown of Primary Research Respondents

2.2.1.1 By industry participant

2.2.1.2 By company type

Chapter 3. Executive Summary

Chapter 4. Pipeline Outlook

4.1 Disease Overview

4.2 Sign & Symptoms

4.3 Epidemiology

4.4 Causes

4.5 Diagnosis

4.6 Prevention and Treatment

4.7 Key Drivers

4.7.1 Driver 1

4.7.2 Driver 2

4.8 Key Barriers

4.8.1 Barrier 1

4.9 RLS Therapeutics Pipeline Analysis

4.9.1 Pipeline Analysis by Phase

4.9.2 Pipeline Analysis by Molecule Type

4.9.3 Pipeline Analysis by Route of Administration

4.9.4 Pipeline Analysis by Company

Chapter 5. RLS Therapeutics Pipeline Analysis by Phase (2018)

5.1 Phase III

5.1.1 NLS-2

5.2 Phase II

5.2.1 BP1.4979

5.2.1.1 Clinical trials

5.2.2 Xxxx

5.2.2.1 Clinical trials

5.2.2.2 Clinical trials results

5.2.3 Xxxx

5.2.3.1 Clinical trials

5.2.3.2 Strategic development

5.2.3.3 Technology

5.2.4 Xxxx

5.2.4.1 Clinical trials

5.2.4.2 Strategic development

5.2.5 Xxxx

5.2.5.1 Clinical trials

5.2.5.2 Technology

5.3 Pre-Clinical

5.3.1 OMS527

5.3.1.1 Strategic development

5.3.2 Xxxx

5.3.2.1 Clinical trials

5.3.2.2 Technology

Chapter 6. Clinical Trials Review

6.1 Clinical Trials by Region

6.2 Clinical Trials by Trial Status

Chapter 7. Competitive Landscape

7.1 Key Player Benchmarking for RLS Therapeutics Pipeline

7.2 SWOT Analysis of RLS Therapeutics Pipeline

Chapter 8. Company Profiles

8.1 NLS Pharma Group

8.1.1 Business Overview

8.1.2 Product Offerings

8.2 Xxxx

8.2.1 Business Overview

8.2.2 Product Offerings

8.3 Xxxx

8.3.1 Business Overview

8.3.2 Product Offerings

8.4 Xxxx

8.4.1 Business Overview

8.4.2 Product Offerings

8.5 Xxxx

8.5.1 Business Overview

8.5.2 Product Offerings

8.6 Xxxx

8.6.1 Business Overview

8.6.2 Product Offerings

Chapter 9. Appendix

9.1 Abbreviations

9.2 Related Reports

 

List of Tables

 

TABLE 1 PIPELINE ANALYSIS OF RLS THERAPEUTICS, BY COMPANY (2018)

TABLE 2 DESCRIPTION OF NLS-2

TABLE 3 DESCRIPTION OF XXXX

TABLE 4 DESCRIPTION OF XXXX

TABLE 5 CLINICAL TRIALS OF XXXX

TABLE 6 DESCRIPTION OF XXXX

TABLE 7 DESCRIPTION OF XXXX

TABLE 8 DESCRIPTION OF XXXX

TABLE 9 CLINICAL TRIALS OF XXXX

TABLE 10 DESCRIPTION OF OMS527

TABLE 11 DESCRIPTION OF XXXX

TABLE 12 NLS PHARMA GROUP - AT A GLANCE

TABLE 13 XXXX – AT A GLANCE

TABLE 14 XXXX – AT A GLANCE

TABLE 15 XXXX – AT A GLANCE

TABLE 16 XXXX – AT A GLANCE

TABLE 17 XXXX – AT A GLANCE

 

List of Figures

 

FIG 1: RESEARCH METHODOLOGY

FIG 2: BREAKDOWN OF PRIMARY RESEARCH RESPONDENTS, BY INDUSTRY PARTICIPANT

FIG 3: BREAKDOWN OF PRIMARY RESEARCH RESPONDENTS, BY COMPANY TYPE

FIG 4: RLS DRUG CANDIDATES IN DEVELOPMENT (2018)

FIG 5: RLS PIPELINE SPLIT, BY MOLECULE TYPE (2018)

FIG 6: RLS PIPELINE SPLIT, BY ROUTE OF ADMINISTRATION (2018)

FIG 7: BREAKDOWN OF CLINICAL TRIALS, BY REGION

FIG 8: BREAKDOWN OF CLINICAL TRIALS, BY TRIAL STATUS

FIG 9: KEY PLAYER BENCHMARKING

FIG 10: SWOT ANALYSIS